Uncertainties around plant inspection timelines of the US Food and Drug Administration were a recurrent topic of discussion at the fiscal first-quarter earnings briefings of front-line Indian firms, with most hopeful that audit schedules will hold and others indicating their readiness for remote interactive evaluations.
The FDA told the Pink Sheet that in view of the uncertainty of the pandemic, the agency is weighing all...





